ULB – “Cellule Europe”

European Liaison Office

ulb-europe@ulb.ac.be
http://www.ulb.ac.be/dr/cellule-europe/
+32 2 650 4288, +32 2 650 6718
Where is Cellule Europe situated?

Research Administration Department

Technology Transfer Office

Cellule Research

Cellule Doctorate

Cellule Contracts

Cellule Europe
What is Cellule Europe’s role?

Support along the project life-cycle (upstream & downstream)

Intermediary between research team & funding agency

To be continued...
Who is Cellule Europe?

- Vanessa Gemis
  - Background: Languages and Letters
  - Responsible for Social Sciences & Humanities domain

- To be determined as we speak
  - Background: ..... 
  - Responsible for Life Sciences domain

- Anastasios Perimenis
  - Background: Chemical, Environmental, Bio-engineering 
  - Responsible for Applied Sciences and Engineering domain

- Elizabeth Rosic
  - Administrative support, communication, databases, statistics, archiving, ...

ulb-europe@ulb.ac.be  http://www.ulb.ac.be/dr/cellule-europe/
Funding opportunities - Overview

- H2020
- P2P (JPI, Art. 185, ERA-NET)
- PPP (JTI-JU, cPPP)
- Other EU (COST, EUREKA, LIFE+, INTERREG, ...)
- International (NIH, JDRF, WWCR, ...)
- Tenders
## H2020 – Framework Programme

### Excellent Science
- European Research Council (ERC)
- Marie Skłodowska Curie (MSCA)
- Future & Emerging Technologies (FET)
- Research Infrastructures (RI)

### Industrial Leadership
- Leadership in Enabling & Industrial Technologies (LEIT)
  - ICT
  - Nanotechnology
  - Advance Materials
  - Biotechnology
  - Advanced Manufacturing
  - Space
  - Access to risk finance
  - Innovation in SMEs

### Societal Challenges
- Health & Wellbeing
- Food, agriculture, marine, bioeconomy
- Energy
- Transport
- Climate, Environment, Resources
- Europe in a changing world
- Secure societies

### CROSS-CUTTING
- European Institute of Innovation & Technology (EIT)
- EURATOM
  - Science with and for Society (SWAFS)
- Spreading Excellence & Widening Participation (SEWP)
## ERC – Frontier research

### Starting (STG)
- $2y < \text{PhD} \leq 7y$
- $1.5 \text{ M€ for 5 years} (+0.5 \text{ M€})$

### Consolidator (COG)
- $7y < \text{PhD} \leq 12y$
- $2.0 \text{ M€ for 5 years} (+0.75 \text{ M€})$

### Advanced (ADV)
- $12y < \text{PhD}$
- $2.5 \text{ M€ for 5 years} (+1.0 \text{ M€})$

### Proof of Concept (POC)
- For ERC grantees (150 k€, 18 months)

### Scientific panels
- Life Sciences (9)
- Social Sciences & Humanities (6)
- Physical Sciences & Engineering (10)

- **Scientific excellence (project and PI)**
- **Feasibility but also high-risk/high-gain**
- **Ground-breaking nature**
- **Reasonably interdisciplinary**
MSCA – Researcher Training

**Individual Fellowships (IF)**
- Standard European Fellowships (EF)
- Career Restart (CR)
- Reintegration (RI)
- Global Fellowships (GF)

**Innovative Training Network (ITN)**
- European Training Network (ETN)
- European Industrial Doctorates (EID)
- European Joint Doctorates (EJD)

**Research and Innovation Staff Exchange (RISE)**
International & Intersectoral staff exchange (research, administrative, technical)

**Co-funding of Regional, National and International Programmes (COFUND)**
Co-financing of experienced/early-stage researcher fellowship programmes

- High quality training to increase employability and career perspectives
FET – New technologies

**FET-OPEN**
- Novel ideas for radically new technologies

**FET-PROACTIVE**
- Clustering around future technologies to build critical mass of knowledge and excellence

**FET-FLAGSHIP**
- Large-scale research for common goal

- GRAPHENE
- Human Brain Project

- FET-OPEN: Highly competitive
  - Example: Call 2014-2015 → cut-off 31/03/2015: 1.8% success rate
LEIT – Industrial perspective

Nanotechnology
Advanced Materials
Biotechnology
Advanced Processing

• Nanomedicine
  • (Bio)catalysis
  • Energy applications
  • Downstream processing
  • Molecular farming
  • ....

Information & Communication Technologies

• Future Internet (5G)
  • Big data
  • Photonics
  • Robotics
  • Cloud computing
  • ....

Space

• Earth Observation
  • Technologies (e.g. propulsion, robotics, station keeping)
  • Satellite Navigation
  • ....

✓ Not “just” research → industrial/market potential

See also PPP *
See also cross-cutting *
SC – Focus on societal needs

**Health**
- Rare & chronic diseases
- eHealth
- Personalised medicine
- Big Data for Public Health policies
- ...

**Well-being**

**Demographic change**

**Food security,**
- Efficient value chains
- Smart primary production
- Healthy & safe food
- Blue growth
- Biomass supply
- Rural economies
- ...

**Sustainable agriculture and forestry**
- Healthy & safe food
- Blue growth
- Biomass supply
- Rural economies
- ...

**Marine, maritime & inland water**

**Bioeconomy**

**Secure, clean and efficient energy**
- Heating & cooling
- Buildings
- Integrated energy systems
- Renewable energy
- ....
SC – Focus on societal needs

**Societal challenges**

- **Smart, green and integrated transport**
  - Urban mobility
  - ITS
  - Automated transport
  - Green Vehicles
  - ...

- **Climate action**
  - Climate services
  - Low-carbon Europe
  - Raw materials
  - Territorial resilience
  - ...

- **Europe in a changing world**
  - Inclusion
  - Fairness and equality
  - Common engagement
  - European cultural space
  - ...

- **Secure societies**
  - Disaster-resilience
  - Crime & Terrorism
  - Border Security
  - Digital Security
  - ...

*inclusive, innovative and reflective societies*  
*protecting freedom and security of Europe and its citizens*
Further pillars

• Cross-cutting activities
  – Not attributable to one pillar, addressing simultaneous challenges
  – Circular economy, internet of things, smart & sustainable cities,…

• Science with and for the Society (SWAFS)
  – Responsible Research and Innovation (gender, ethics,…)

• Spreading excellence and widening participation (SEWP)
  – WIDESPREAD Character of R&I: Teaming & Twinning

• EURATOM

• European Institute for Science & Technology (EIT)
  – Knowledge Innovation Communities (KICs)
    • Triangle structure: Education, Research & Innovation, Entrepreneurship
    • KICs: Climate, Digital, InnoEnergy, Health, Raw Materials, Added-value manufacturing, Food4Future, Urban Mobility
General info

• **Everything** you need is in the Participant Portal


- Call openings
- “How to” guides
- H2020 Online manual
- Work programmes 2016-2017
- Templates
- Reference documents (e.g. model grant agreement)
- Partnering platforms
- Submission platform
- Registering as an expert
- Helpdesk
- .....
General info

• How to read a call/topic (example):
  – Pillar 3: Societal challenges
    o Challenge 1: Health, well-being & demographic change
      ❖ Call name: Personalised Medicine / H2020-SC1-2016-2017
      ➢ Topic name: New therapies for chronic diseases / SC1-PM-09-2016
• **Types of action (collaborative projects)**
  – Depending on the call and the maturity of the technology/concept (TRL)
    • Research and Innovation Action (RIA)
    • Innovation Action (IA)
    • Coordination and Support Action (CSA)
  – Funding rate at 100% for non-profit organisations

• **Typical proposal structure & evaluation criteria**
  – Excellence (science: objectives, concept, methodology)
  – Impact (measurable & realistic, measures to maximise it)
  – Implementation (work description, time plan, operational capacity)
General info

• National Contact Points
  – Support in proposal preparation
  – Partnering possibilities
    • NCP Brussels  www.ncpbrussels.be
    • NCP Wallonia  www.ncpwallonie.be
    • NCP FNRS      www.ncp.frs-fnrs.be
    • NCP BELSPO    www.eurofed.stis.belspo.be

• Financial support ("Prime")
  – FNRS
  – Brussels Region (Innoviris)
  – Walloon Region (DG 06)
Funding opportunities - Overview

- H2020
- P2P (JPI, Art. 185, ERA-NET)
- PPP (JTI-JU, cPPP)
- Other EU (COST, EUREKA, LIFE+, INTERREG, ...)
- International (NIH, JDRF, WWCR, ...)
- Tenders
Partnerships in the European Research Area (ERA)

<table>
<thead>
<tr>
<th>Partnerships</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPP (Public/Private Partnership)</td>
</tr>
<tr>
<td>Joint Technology Initiative (JTI)</td>
</tr>
<tr>
<td>Contractual PPP (cPPP)</td>
</tr>
<tr>
<td>P2P (Public/Public Partnership)</td>
</tr>
<tr>
<td>Joint Programming Initiatives (JPI)</td>
</tr>
<tr>
<td>Article 185 Initiatives</td>
</tr>
<tr>
<td>European Research Area Networks (ERA-NET)</td>
</tr>
</tbody>
</table>
Partnerships in the European Research Area (ERA)

**Partnerships**

**PPP**
(Public/Private Partnership)

- Joint Technology Initiative (JTI)
- Contractual PPP (cPPP)

**P2P**
(Public/Public Partnership)

- Joint Programming Initiatives (JPI)
- Article 185 Initiatives
- European Research Area Networks (ERA-NET)

- Institutional PPPs (article 187 of the TFEU)
- Own legal entity in form of a Joint Undertaking (JU)
- Follow the rules of H2020
- Manage own calls (appearing in Participant Portal)
- Budget totally earmarked for the entire duration
## Partnerships in the European Research Area (ERA)

### Partnerships

<table>
<thead>
<tr>
<th>PPP (Public/Private Partnership)</th>
<th>P2P (Public/Public Partnership)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint Technology Initiative (JTI)</td>
<td>Contractual PPP (cPPP)</td>
</tr>
<tr>
<td></td>
<td>Joint Programming Initiatives (JPI)</td>
</tr>
<tr>
<td></td>
<td>Article 185 Initiatives</td>
</tr>
<tr>
<td></td>
<td>European Research Area Networks (ERA-NET)</td>
</tr>
</tbody>
</table>

- Electronic Components and Systems for European (ECSEL) *
  - [www.ecsel-ju.eu](http://www.ecsel-ju.eu)
- Bio-Based Industries (BBI)
  - [www.bbi-europe.eu](http://www.bbi-europe.eu)
- Innovative Medicine Initiative 2 (IMI2)
  - [www.imi.europa.eu](http://www.imi.europa.eu)
- Fuel Cells and Hydrogen 2 (FCH2)
  - [www.fch.europa.eu](http://www.fch.europa.eu)
- Clean Sky 2 (CS2)
  - [www.cleansky.eu](http://www.cleansky.eu)
- Shift²Rail (S2R)
  - [www.shift2rail.org](http://www.shift2rail.org)
- Single European Sky Air Traffic Management Research (SESAR) *
  - [www.sesarju.eu](http://www.sesarju.eu)
Partnerships in the European Research Area (ERA)

- **PPP (Public/Private Partnership)**
  - Joint Technology Initiative (JTI)
  - Contractual PPP (cPPP)

- **P2P (Public/Public Partnership)**
  - Joint Programming Initiatives (JPI)
  - Article 185 Initiatives
  - European Research Area Networks (ERA-NET)

- Ad-hoc contractual agreements
- No stand-alone legal entity
- Follow the rules of H2020
- Calls managed by EC (appearing in Participant Portal)
- Budget not entirely earmarked
Partnerships in the European Research Area (ERA)

**Partnerships**

<table>
<thead>
<tr>
<th>PPP (Public/Private Partnership)</th>
<th>P2P (Public/Public Partnership)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint Technology Initiative (JTI)</td>
<td>Contractual PPP (cPPP)</td>
</tr>
<tr>
<td>Joint Programming Initiatives (JPI)</td>
<td>Article 185 Initiatives</td>
</tr>
<tr>
<td>European Research Area Networks (ERA-NET)</td>
<td></td>
</tr>
</tbody>
</table>

- Sustainable Process Industries (SPIRE) [www.spire2030.eu](http://www.spire2030.eu)
- Advanced 5G Network Infrastructure (5G) [www.5g-ppp.eu](http://www.5g-ppp.eu)
- European Green Vehicles Initiative (EGVI) [www.egvi.eu](http://www.egvi.eu)
- Robotics (SPARC) [www.sparc-robotics.eu](http://www.sparc-robotics.eu)
- Energy-Efficient Buildings (EeB) [www.e2b-ei.eu](http://www.e2b-ei.eu)
- Factories of the Future (FoF) [www.effra.eu](http://www.effra.eu)
- High Performance Computing (HPC) [www.etp4hpc.eu](http://www.etp4hpc.eu)
- Photonics [www.photonics21.org](http://www.photonics21.org)
- Big data [www.bdva.eu](http://www.bdva.eu)
Partnerships in the European Research Area (ERA)

**Partnerships**

- **PPP** (Public/Private Partnership)
  - Joint Technology Initiative (JTI)
  - Contractual PPP (cPPP)
- **P2P** (Public/Public Partnership)
  - Joint Programming Initiatives (JPI)
  - Article 185 Initiatives
  - European Research Area Networks (ERA-NET)

- Initiatives of a long-term perspective
- Addressing major European societal challenges
- Pooling & aligning research in Member States
- Focusing on institutionalised funding
- Developing a common Strategic Research Agenda
- Opening joint calls
- National funding rules apply
Partnerships in the European Research Area (ERA)

**Partnerships**

PPP  
(Public/Private Partnership)

- Joint Technology Initiative (JTI)
- Contractual PPP (cPPP)

P2P  
(Public/Public Partnership)

- Joint Programming Initiatives (JPI)
- Article 185 Initiatives
- European Research Area Networks (ERA-NET)

- Neurodegenerative Diseases (JPND)  
  [www.neurodegenerationresearch.eu](http://www.neurodegenerationresearch.eu)
- Agriculture, Food Security and Climate Change (FACCE)  
  [www.faccejpi.com](http://www.faccejpi.com)
- A Healthy Diet for a Healthy Life (HDHL)  
  [www.healthydietforhealthylife.eu](http://www.healthydietforhealthylife.eu)
- Cultural Heritage and Global Change (JPICH)  
  [www.jpi-culturalheritage.eu](http://www.jpi-culturalheritage.eu)
- Urban Europe (JPIUE)  
  [www.jpi-urbaneurope.eu](http://www.jpi-urbaneurope.eu)
- Connecting Climate Knowledge for Europe (JPI Climate)  
  [www.jpi-climate.eu](http://www.jpi-climate.eu)
- More Years, Better Lives (MYBL)  
  [www.jp-demographic.eu](http://www.jp-demographic.eu)
- Antimicrobial Resistance (JPIAMR)  
  [www.jpiamr.eu](http://www.jpiamr.eu)
- Water Challenges for a Changing World (Water JPI)  
  [www.waterjpi.eu](http://www.waterjpi.eu)
- Healthy and Productive Seas and Oceans (JPI Oceans)  
  [www.jpi-oceans.eu](http://www.jpi-oceans.eu)
Partnerships in the European Research Area (ERA)

<table>
<thead>
<tr>
<th>Partnerships</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPP (Public/Private Partnership)</td>
</tr>
<tr>
<td>Joint Technology Initiative (JTI)</td>
</tr>
<tr>
<td>Joint Programming Initiatives (JPI)</td>
</tr>
<tr>
<td>European Research Area Networks (ERA-NET)</td>
</tr>
</tbody>
</table>

- Foreseen in article 185 of the TFEU
- Involving EU in joint research programmes of Member States (organisation, funding, implementation)
Partnerships in the European Research Area (ERA)

**Partnerships**

**PPP**
(Public/Private Partnership)

- Joint Technology Initiative (JTI)
- Contractual PPP (cPPP)

**P2P**
(Public/Public Partnership)

- Article 185 Initiatives
- European Research Area Networks (ERA-NET)

- Active and Assisted Living 2 (AAL2)

- Eurostars 2 * → see also EUREKA instrument

- European and Developing Countries Clinical Trials Partnership 2 (EDCTP)

- European Metrology Programme for Innovation and Research (EMPIR)

[www.aal-europe.eu](http://www.aal-europe.eu)
[www.eurostars-eureka.eu](http://www.eurostars-eureka.eu)
[www.edctp.org](http://www.edctp.org)
[www.msu.euramet.org](http://www.msu.euramet.org)
Partnerships

PPP
(Public/Private Partnership)

P2P
(Public/Public Partnership)

Joint Technology Initiative (JTI)

Contractual PPP (cPPP)

Joint Programming Initiatives (JPI)

Article 185 Initiatives

European Research Area Networks (ERA-NET)

- Avoiding fragmentation and overlapping in transnational & regional research
- Theme-specific research programmes (smaller scale initiatives)
- Linked or not to JPI
- H2020: ERA-NET Cofund (one compulsory joint call with EU top-up funding)
  - Merger of ERA-NET and ERA-NET+ from FP7 (some still on going)
- National/Regional funding rules apply
Partnerships in the European Research Area (ERA)

Partnerships

PPP
(Public/Private Partnership)

Joint Technology Initiative (JTI)

Contractual PPP (cPPP)

Joint Programming Initiatives (JPI)

P2P
(Public/Public Partnership)

Article 185 Initiatives

European Research Area Networks (ERA-NET)

WaterWorks2014 Water
Neuron COFUND
SusAn
WaterWorks2015 Water
JPI-EC-AMR JPIAMR
ERA-CVD
FACCE-SURPLUS FACCE

WaterWorks2014 Water
DemoWind
SmartGridPlus
ERACoSysMed
HERA JRP UP
TRANSCAN-2

E-Rare-3
ENSCE JPIEU
JPco-fuND JPND
BiodivERsA3

ERA-NET COFUND actions where Belgium is active

For an overview of existing & forthcoming ERA-NETs visit: www.era-learn.eu
<table>
<thead>
<tr>
<th>FNRS</th>
<th>Walloon Region</th>
<th>Brussels Region</th>
<th>Federal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>JTI</strong></td>
<td>-</td>
<td>-</td>
<td><strong>ECSEL</strong></td>
</tr>
<tr>
<td><strong>JPI</strong></td>
<td>All</td>
<td>FACCE, JPIUE</td>
<td>JPIUE</td>
</tr>
<tr>
<td><strong>Art. 185</strong></td>
<td>-</td>
<td>AAL, Eurostars2</td>
<td>AAL, Eurostars2</td>
</tr>
<tr>
<td><strong>ERA-NET</strong>&lt;br&gt;(all types)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* ERA-NET COFUND, ERA-NET+, ERA-NET*
Funding opportunities - Overview

- H2020
- P2P (JPI, Art. 185, ERA-NET)
- PPP (JTI-JU, cPPP)
- Other EU (COST, EUREKA, LIFE+, INTERREG, ...)
- International (NIH, JDRF, WWCR, ...)
- Tenders
- ....
Other EU (examples)

3rd Health Programme
Examples from 2015 call
(tuberculosis, viral hepatitis, transplantation therapies, availability of alcoholic beverages, integrated care, ...)
New call expected early summer 2016

Consumer Programme

Justice Programme

Available in Participant Portal
Other EU (examples)

**COST**
Cooperation in Science & Technology

- Funding of networking activities
  - Ideal for building / maintaining consortia
- Managed through National Coordinators (CNC)
  - Two representatives per country

**EUREKA**
Innovation across borders

- Inter-governmental network
  - Brussels & Wallonia participating
- Supports market-oriented R&D&I projects

- Network projects
- Clusters
- Eurostars 2 *
- Umbrellas
Other EU (examples)

**LIFE+**
Programme for the Environment and Climate Action

- Financial instrument for the Environment

**Nature and Biodiversity / Environment / Climate action**
- Traditional projects
- Preparatory projects
- Integrated projects
- Technical assistance projects
- Capacity building projects

**INTERREG EUROPE**

- Supporting governments develop policy
  - Interregional cooperation projects
  - Policy learning platforms

**Research & Innovation**
- SME Competitiveness
- Environment & Resource Efficiency
- Low-carbon economy
Funding opportunities - Overview

- H2020
- P2P (JPI, Art. 185, ERA-NET)
- PPP (JTI-JU, cPPP)
- Other EU (COST, EUREKA, LIFE+, INTERREG, ...)
- International (NIH, JDRF, WWCR, ...)
- Tenders
International

- National Institute of Health (NIH)  

- Juvenile Diabetes Research Fund (JDRF)  

- Worldwide Cancer Research (WWCR)  

- American Association for Cancer Research (AICR)  
  [http://www.aacr.org](http://www.aacr.org)

- European Foundation for the Study of Diabetes (EFSD)  

- ...

✓ Varying conditions for participation, institutional registration often required
Funding opportunities - Overview

- H2020
- P2P (JPI, Art. 185, ERA-NET)
- PPP (JTI-JU, cPPP)
- Other EU (COST, EUREKA, LIFE+, INTERREG, ...)
- International (NIH, JDRF, WWCR, ...)
- Tenders
Tenders

• Public procurement
  – Directorates-General
  – European Network/Agencies (ESPON, EUMETSAT,...)
  – Available in TED Home (Tenders Electronic Daily)
  – Different administrative requirements than H2020
Funding opportunities - Overview

- H2020
- P2P (JPI, Art. 185, ERA-NET)
- PPP (JTI-JU, cPPP)
- Other EU (COST, EUREKA, LIFE+, INTERREG, ...)
- International (NIH, JDRF, WWCR, ...)
- Tenders
What is Cellule Europe’s role?

Support along the project life-cycle (upstream & downstream)

Intermediary between research team & funding agency
What can Cellule Europe offer?

- Information on funding schemes
  - General info sessions / Personalised meetings
  - Circulation of draft documents

- Identification of concrete funding opportunities
  - Adapted to research team

- Identification of partnering options
  - Increase visibility
  - Collaboration with NCPs & European Liaison Offices
What can Cellule Europe offer?

• Assistance in proposal preparation & submission
  – Administrative aspects (eligibility, budget, declarations, completeness, submission platform, financial support, ...)
  – Scientific aspects

• Critical reviewing of proposals
  – Systematically for ERC (and MSCA) by external consultant

Call opening

- General info session
- Deadline 1st draft
- Interest confirmed
- First review round
- Meetings with consultant
- Budget (with us)
- Second review round
- Deadline 2nd draft
- Submission
What can Cellule Europe offer?

• Management of administrative aspects
  – Grant Agreement,
  – Consortium Agreement,
  – Amendments
  – ...

• Contact with ULB Departments
  – Technology Transfer Office
  – Financial Department
  – Human Resources Department
What can you do?

- Register at and consult **Infofin**, [http://infofin.ulb.ac.be/](http://infofin.ulb.ac.be/)
- **Contact us** at any stage
- Consult the relevant documentation (e.g. WP 2016-2017)
- Extend to your contact network
- Increase your visibility
- Register as an expert
- Try...

✔ Help Cellule Europe reach every scientific team
ULB – “Cellule Europe”

European Liaison Office
ulb-europe@ulb.ac.be
http://www.ulb.ac.be/dr/cellule-europe/
+32 2 650 4288, +32 2 650 6718
What is Cellule Europe managing?

<table>
<thead>
<tr>
<th>Type</th>
<th>FP7</th>
<th>H2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collaborative*</td>
<td>103</td>
<td>14</td>
</tr>
<tr>
<td>ERC</td>
<td>17</td>
<td>3</td>
</tr>
<tr>
<td>MCSA</td>
<td>37</td>
<td>6</td>
</tr>
</tbody>
</table>

*Only EU Framework projects (without PPP, P2P, International, Tenders,...)*
• Advanced materials and nanotechnologies for healthcare
  • Biomaterials for diagnosis and treatment of demyelination disorders of the Central Nervous System
  • Nanoformulation of biologicals
  • ERA-NET on Nanomedicine
  • Development of a reliable methodology for better risk management of engineered biomaterials in Advanced Therapy Medicinal Products and/or Medical Devices
  • Cross-cutting KETs for diagnostics at the point-of-care
  • Regulatory Science Framework for assessment of risk benefit ratio of Nanomedicines and Biomaterials
  • Nanotechnologies for imaging cellular transplants and regenerative processes in vivo
  • Mobilising the European nano-biomedical ecosystem

• Personalised medicine
  – Understanding health, well-being and disease
    • Multi omics for personalised therapies addressing diseases of the immune system
    • New concepts in patient stratification
    • Diagnostic characterisation of rare diseases
    • Networking and optimising the use of population and patient cohorts at EU level

  – Preventing disease
    • The European Human Biomonitoring Initiative
    • Vaccine development for malaria and/or neglected infectious diseases
    • Promoting mental health and well-being in the young

Personalised medicine

- Treating and managing diseases
  - New therapies for **rare diseases**
  - New therapies for **chronic diseases**
  - Comparing the **effectiveness of existing healthcare interventions** in the adult population
  - Clinical research on **regenerative medicine**

- Active ageing and self-management of health
  - **PCP - eHealth innovation** in empowering the patient
  - **PPI for deployment and scaling up of ICT solutions for active and healthy ageing**
  - **EU-Japan cooperation on Novel ICT Robotics** based solutions for active and healthy ageing at home or in care facilities
  - **Personalised coaching** for well-being and care of people as they age
• **Personalised medicine**
  – Methods and data
    • *In-silico trials for developing and assessing biomedical products*
    • *Personalised computer models* and in-silico systems for well-being
    • *Big Data* supporting Public Health policies
    • *PPI* for uptake of *standards for the exchange of digitalised healthcare records*
    • *Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector*

  – Health care provision and integrated care
    • *Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries*
• Coordination activities
  - Valorisation of FP7 Health and H2020 SC1 research results
  - Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine
  - Implementing the Strategic Research Agenda on Personalised Medicine
  - Towards globalisation of the JPI on Antimicrobial resistance
  - Coordinating personalised medicine research
  - Towards an ERA-NET for building sustainable and resilient health system models
  - Global Alliance for Chronic Diseases (GACD)
  - Actions to bridge the divide in European health research and innovation
  - Support for Europe’s leading Health ICT SMEs
• Coordination activities
  • Coordinated action to support the recognition of Silver Economy opportunities arising from demographic change
  • Digital health literacy
  • Healthcare Workforce IT skills
  • EU-US interoperability roadmap
  • EU eHealth Interoperability conformity assessment
  • Standardisation needs in the field of ICT for Active and Healthy Ageing
• 6\textsuperscript{th} call (Deadline 12/01/2016 for 1\textsuperscript{st} stage)
  • Development of \textit{Quantitative System Toxicology (QST)} approaches to improve the understanding of the \textit{safety} of new medicines
  • Establishing impact of \textit{RSV (respiratory syncytial virus)} infection, resultant disease and public health approach to reducing the consequences
  • Real World Outcomes Across the \textit{AD (Alzheimer’s disease)} Spectrum (ROADS) to Better Care
  • Development of an outcomes-focused platform to empower policy makers and clinicians to optimise care for patients with \textit{haematologic malignancies}

\textit{http://www.imi.europa.eu/content/imi-2-call-6-0}
• **Future topics**
  
  • Ebola and other filoviral haemorrhagic fevers (*Ebola*) programme: future outbreaks
  
  • Validation of translational imaging methods in drug safety assessment (TRISTAN)
  
  • Identification of **drugable targets modulating misfolded proteins** in major neurodegenerative diseases
  
  • Pathological **neuron-glia interactions** in neuropathic pain
  
  • **Dry age-related macular degeneration**: development of novel clinical endpoints for clinical trials with a regulatory and patient access intention
  
  • A comprehensive ‘**paediatric preclinical POC platform**’ to enable clinical molecule development for children with cancer
  
  • Identification and validation of non-invasive markers across the spectrum of **nonalcoholic fatty liver disease** (NAFLD)
  
  • Coordination and support action (CSA) for the **big data** for better outcomes programme
  
  • Increase access and use of high quality data to improve clinical outcomes in **heart failure** (HF), **atrial fibrillation** (AF), and **acute coronary syndrome** (ACS) patients
Joint Programming Initiatives

• Neurodegenerative Diseases (JPND)
  ✓ New call anticipated January 2016, deadline March 2016
    – Harmonisation and Alignment in Brain Imaging Methods for Neurodegeneration
      http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/open-calls/

• Antimicrobial Resistance (JPAMR)
  ✓ New call anticipated January 2016 (JPI-EC-AMR: ERA-NET Cofund)
    – Transmission Dynamics
  ✓ New call anticipated April 2016, deadline June 2016
    – Networking programmes
      http://www.jpiamr.eu/activities/joint-calls/
European & Developing Countries Clinical Trials Partnership (EDCTP)

- Ethics and Regulatory Capacities (deadl. 01/2016)
- Clinical Research and Development Fellowships (deadl. 01/2016)
- Regional Networks (deadl. 02/2016)
- Career Development Fellowships (deadl. 02/2016)
- Senior Fellowships (deadl. 02/2016)

http://www.edctp.org/funding-opportunities/calls/
• **NEURON Cofund**
  
  ✓ 2015 calls: Neurodevelopmental disorders, neuroethics (closed)
  
  ✓ New call anticipated in January 2016
  

• **Aligning transnational cancer research (TRANSCAN-2)**

  ✓ Immunology and immunotherapy of cancer: strengthening the translational aspects → Launching December 2015
  
  [http://www.transcanfp7.eu](http://www.transcanfp7.eu)

• **Cardiovascular diseases (ERA-CVD)**

  ✓ No call yet, anticipated in 2016
ERA-NET Cofund

- Systems Medicine to address clinical needs (ERACoSysMed)
  - 2015 call: Socioeconomic benefit of systems medicine approach (closed)
  - 2016: ?
    - https://www.eracosysmed.eu

- Research Programme on Rare Diseases (E-Rare-3)
  - Joint Call 2016: Clinical research for new therapeutic uses of already existing molecules (repurposing) in rare diseases → Launching December 2015
    - http://www.erare.eu/
ERC Life Science panels

**Life Sciences**

**LS1 Molecular and Structural Biology and Biochemistry**
Molecular synthesis, modification and interaction, biochemistry, biophysics, structural biology, metabolism, signal transduction.

**LS2 Genetics, Genomics, Bioinformatics and Systems Biology**
Molecular and population genetics, genomics, transcriptomics, proteomics, metabolomics, bioinformatics, computational biology, biostatistics, biological modelling and simulation, systems biology, genetic epidemiology.

**LS3 Cellular and Developmental Biology**
Cell biology, cell physiology, signal transduction, organogenesis, developmental genetics, pattern formation in plants and animals, stem cell biology.

**LS4 Physiology, Pathophysiology and Endocrinology**
Organ physiology, pathophysiology, endocrinology, metabolism, ageing, tumorigenesis, cardiovascular disease, metabolic syndrome.

**LS5 Neurosciences and Neural Disorders**
Neurobiology, neuroanatomy, neurophysiology, neurochemistry, neuropharmacology, neuroimaging, systems neuroscience, neurological and psychiatric disorders.

**LS6 Immunity and Infection**
The immune system and related disorders, infectious agents and diseases, prevention and treatment of infection.

**LS7 Diagnostic Tools, Therapies and Public Health**
Aetiology, diagnosis and treatment of disease, public health, epidemiology, pharmacology, clinical medicine, regenerative medicine, medical ethics.

**LS8 Evolutionary, Population and Environmental Biology**

**LS9 Applied Life Sciences and Non-Medical Biotechnology**
Applied plant and animal sciences, food sciences, forestry, industrial, environmental and non-medical biotechnologies, bioengineering, synthetic and chemical biology, biomimetics, bioremediation.